The potential effects of clinical antidiabetic agents on SARS-CoV-2.

ABSTRACT:

Background

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is currently posing significant threats to public health worldwide. It is notable that a substantial proportion of patients with sever COVID-19 have coexisting diabetic conditions, indicating the progression and outcome of COVID-19 may relate to diabetes. However, it is still unclear whether diabetic treatment principles can be used for the treatment of COVID-19.

Methods

We conducted a computational approach to screen all commonly used clinical oral hypoglycemic drugs to identify the potential inhibitors for the main protease (M^pro ) of SARS-CoV-2, which is one of the key drug targets for anti-COVID-19 drug discovery.

Results

Six antidiabe

SUBMITTER: Qu H 

PROVIDER: S-EPMC7753367 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature